The Federal Circuit's recent ruling that patents listed in the FDA's Orange Book must cover the active ingredient of a drug has sparked significant debate in the pharmaceutical industry. The court's ...

The US Court of Appeals for the Federal Circuit affirmed a district court’s delisting of patents from the Orange Book because the patent claims ...